HomeCompareDMTK vs SPHD

DMTK vs SPHD: Dividend Comparison 2026

DMTK yields 2127.66% · SPHD yields 4.33%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 DMTK wins by $17707088693.35M in total portfolio value
10 years
DMTK
DMTK
● Live price
2127.66%
Share price
$0.09
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$17707088693.38M
Annual income
$16,208,512,607,342,262.00
Full DMTK calculator →
SPHD
SPHD
● Live price
4.33%
Share price
$49.34
Annual div
$2.14
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$26.5K
Annual income
$571.32
Full SPHD calculator →

Portfolio growth — DMTK vs SPHD

📍 DMTK pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodDMTKSPHD
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, DMTK + SPHD cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
DMTK pays
SPHD pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

DMTK
Annual income on $10K today (after 15% tax)
$180,851.06/yr
After 10yr DRIP, annual income (after tax)
$13,777,235,716,240,922.00/yr
SPHD
Annual income on $10K today (after 15% tax)
$367.92/yr
After 10yr DRIP, annual income (after tax)
$485.62/yr
At 15% tax rate, DMTK beats the other by $13,777,235,716,240,436.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of DMTK + SPHD for your $10,000?

DMTK: 50%SPHD: 50%
100% SPHD50/50100% DMTK
Portfolio after 10yr
$8853544346.70M
Annual income
$8,104,256,303,671,417.00/yr
Blended yield
91.54%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on DMTK right now

DMTK
Analyst Ratings
3
Buy
4
Hold
Consensus: Hold
Price Target
$7.50
+7878.7% upside vs current
Range: $7.50 — $7.50
Altman Z
-8.4
Piotroski
4/9
SPHD
No analyst data
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

DMTK buys
0
SPHD buys
0
No recent congressional trades found for DMTK or SPHD in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricDMTKSPHD
Forward yield2127.66%4.33%
Annual dividend / share$2.00$2.14
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%0%
Portfolio after 10y$17707088693.38M$26.5K
Annual income after 10y$16,208,512,607,342,262.00$571.32
Total dividends collected$17601219228.91M$5.1K
Payment frequencyquarterlyquarterly
SectorStockETF

Year-by-year: DMTK vs SPHD ($10,000, DRIP)

YearDMTK PortfolioDMTK Income/yrSPHD PortfolioSPHD Income/yrGap
1← crossover$223,466$212,765.96$11,133$432.85+$212.3KDMTK
2$4,682,655$4,443,546.58$12,363$450.36+$4.67MDMTK
3$92,031,981$87,021,539.62$13,695$467.39+$92.02MDMTK
4$1,696,889,334$1,598,415,114.79$15,138$483.90+$1696.87MDMTK
5$29,359,261,977$27,543,590,390.03$16,697$499.88+$29359.25MDMTK
6$476,792,027,971$445,377,617,654.91$18,382$515.31+$476792.01MDMTK
7$7,269,883,644,738$6,759,716,174,809.65$20,198$530.17+$7269883.62MDMTK
8$104,104,693,867,782$96,325,918,367,911.80$22,157$544.46+$104104693.85MDMTK
9$1,400,538,398,162,041$1,289,146,375,723,514.20$24,266$558.18+$1400538398.14MDMTK
10$17,707,088,693,375,648$16,208,512,607,342,262.00$26,536$571.32+$17707088693.35MDMTK

DMTK vs SPHD: Complete Analysis 2026

DMTKStock

DermTech, Inc., a molecular diagnostic company, develops and markets novel non-invasive genomics tests to diagnosis skin cancer, inflammatory diseases, and aging-related conditions in the United States. It offers DermTech Melanoma Test (DMT), a gene expression test that enhances early detection of genomic atypia and helps rule out melanoma and the need for a surgical biopsy of atypical pigmented lesions. The company also provides adhesive skin sample collection kits, as well as gene expression assays for the Th1, Th2, IFN-gamma, and Th17 inflammatory pathways. In addition, it is developing UV damage DNA risk assessment products, as well as non-melanoma skin cancer diagnostic and cutaneous T-cell lymphoma rule out test products, as well as offering health-related and information services through electronic information and telecommunication technologies. The company sells its products primarily to pathology and oncology practitioners. DermTech, Inc. is headquartered in La Jolla, California.

Full DMTK Calculator →

SPHDETF

The Invesco S&P 500 High Dividend Low Volatility ETF (Fund) is based on the S&P 500 Low Volatility High Dividend Index (Index). The Fund will invest at least 90% of its total assets in common stocks that comprise the Index. Standard & Poor's compiles, maintains and calculates the Index, which is composed of 50 securities traded on the S&P 500 Index that historically have provided high dividend yields and low volatility. The Fund and the Index are rebalanced and reconstituted semi-annually, in January and July.

Full SPHD Calculator →
📬

Get this DMTK vs SPHD comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

DMTK vs SCHDDMTK vs JEPIDMTK vs ODMTK vs KODMTK vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.